Back

Interrelation between baseline plaque characteristics and changes in coronary atherosclerosis with the PCSK9-inhibitor alirocumab: Insights from the PACMAN-AMI randomized trial

26 August 2022 (08:00 - 19:30)
Organised by:
Congress Presentation Part of: Lipid-lowering therapy and the atheroma Angiography, Invasive Imaging ESC Professional Premium Access ESC Congress 2022

About the speaker

Photo
Doctor Konstantinos Koskinas

Bern University Hospital, Inselspital, Bern (Switzerland)

2 More presentations in this session

Presentation thumbnail
State-of-the-art lecture in lipid lowering therapy and the atheroma .
Professor S. Nicholls (Melbourne, AU)
Slides Video
Presentation thumbnail
Longer-term safety of alirocumab with 24,610 patient-years of placebo-controlled observation: Further insights from the ODYSSEY OUTCOMES trial
Doctor S. Goodman (Toronto, CA)
Abstract Slides Video

Access the full session

Session thumbnail
Lipid-lowering therapy and the atheroma
Video

The Event

Event poster

ESC Congress 2022

26 August - 29 August 2022
You may be interested in
thumbnail
Congress Presentation
Effect of alirocumab on quantitative flow ratio and diameter stenosis in non-infarct related arteries from patients with acute myocardial infarction: a PACMAN-AMI randomized clinical trial substudy
thumbnail
Congress Presentation
High-intensity lipid-lowering therapy accelerates early plaque regression: a FLOWPROMOTE sub study.
thumbnail
Congress Presentation
PCSK9 inhibitors and coronary atherosclerotic plaque modification: a meta-analysis

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources